Evolent Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2018 Annual Meeting of Stockholders held on June 13, 2018. The filing was submitted on June 14, 2018. As of the record date of April 17, 2018, there were 76,984,778 shares of Class A common stock and 880,646 shares of Class B common stock outstanding and entitled to vote.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and voting results. It does not contain financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
There are no material changes to financial operations reported in this document. The filing details the successful ratification of the independent auditor and the approval of an amendment to the 2015 Omnibus Incentive Compensation Plan.
Voting Results and Management Commentary
Stockholders voted on five proposals, all of which were approved by a majority of votes cast:
- Proposal 1 (Election of Directors): Four Class III director nominees (Bruce Felt, Kenneth Samet, Cheryl Scott, Frank Williams) were elected for three-year terms expiring in 2021. Vote counts ranged from approximately 49.8 million to 52.2 million "For" votes.
- Proposal 2 (Ratification of Auditors): PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018, with 69,736,379 "For" votes.
- Proposal 3 (Compensation Plan Amendment): An amendment to the 2015 Omnibus Incentive Compensation Plan was approved with 57,214,041 "For" votes.
- Proposal 4 (Say-on-Pay): Executive compensation for 2017 was approved on an advisory basis with 58,364,125 "For" votes.
- Proposal 5 (Frequency of Say-on-Pay): Stockholders selected a one-year frequency for future advisory votes on executive compensation, with 61,975,282 votes cast for the one-year option.
Investor Verification Checklist
- Verify the definitive proxy statement (Schedule 14A) filed on April 27, 2018, for detailed biographies of the elected directors and specifics of the compensation plan amendment.
- Confirm the total number of shares outstanding and voting rights structure (Class A vs. Class B) in subsequent filings to monitor dilution or changes in capital structure.
- Review the next quarterly or annual report (10-Q or 10-K) for the actual financial performance metrics not included in this 8-K.